NxThera Obtains $12,600,000 Series B Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=167582e4-7aaa-4587-a368-317d55626b7a&Preview=1 -
Date
3/16/2011 -
Company Name
NxThera -
Mailing Address
4186 Lexington Ave. St. Paul, MN 55126 -
Company Description
NxThera develops medical technologies to treat a variety of endourology conditions, including BPH. The company’s technology platform utilizes a simple, minimally invasive, vapor therapy designed to measurably improve urinary flow and patient quality of life. -
Website
http://www.nxthera.com -
Transaction Type
Venture Equity -
Transaction Amount
$12,600,000 -
Transaction Round
Series B -
Proceeds Purposes
The company plans to use this capital to initiate a pivotal BPH clinical study outside of the United States and to obtain CE mark approval needed to support the introduction of its product in the European Economic Area. NxThera also has begun the process of seeking appropriate FDA approvals to undertake a second arm of the BPH clinical study in the U.S. -
M&A Terms
-
Venture Investor
American Medical Systems -
Venture Investor
Arboretum Ventures -
Venture Investor
Aberdare Ventures
